Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2023-11-06 |
2023-09 |
-0.27 |
N/A |
N/A |
N/A |
2023-08-02 |
2023-06 |
-0.56 |
N/A |
N/A |
N/A |
2023-04-27 |
2023-03 |
-0.57 |
N/A |
N/A |
N/A |
2023-03-02 |
2022-12 |
-0.53 |
N/A |
N/A |
N/A |
2022-11-01 |
2022-09 |
5.11 |
N/A |
N/A |
N/A |
2022-08-03 |
2022-06 |
-0.53 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-09-26 |
Canaccord Genuity |
Downgrade |
Buy |
Hold |
2023-09-26 |
HC Wainwright & Co. |
Downgrade |
Buy |
Neutral |
2023-09-26 |
RBC Capital |
Upgrade |
Sector Perform |
Sector Perform |
2023-09-26 |
B. Riley Securities |
Downgrade |
Buy |
Neutral |
2023-08-02 |
Canaccord Genuity |
Upgrade |
Buy |
Buy |
2023-08-02 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2023-05-23 |
AKKARAJU SRINIVAS |
Director |
686.69K |
Stock Award(Grant) |
2023-01-26 |
BERREY M MICHELLE |
Officer |
83.88K |
Stock Award(Grant) |
2023-05-23 |
BRADBURY DANIEL M |
Director |
39.47K |
Stock Award(Grant) |
2023-05-23 |
FUNDARO PAOLO |
Director |
43.91K |
Stock Award(Grant) |
2023-05-23 |
GOTTESDIENER KEITH MICHAEL |
Director |
32.83K |
Stock Award(Grant) |
2023-05-23 |
LUCA BENATTI |
Director |
33.60K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Group Inc |
4.69M |
51.91M |
11.23% |
2023-06-29 |
Blackrock Inc. |
4.40M |
48.63M |
10.52% |
2023-06-29 |
State Street Corporation |
4.18M |
46.23M |
10.00% |
2023-06-29 |
Deerfield Management Company, L.P. (Series C) |
2.08M |
22.98M |
4.97% |
2023-06-29 |
UBS Group AG |
1.36M |
15.04M |
3.25% |
2023-06-29 |
Caligan Partners, LP |
1.29M |
14.31M |
3.10% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-08-30 |
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF |
3.47M |
37.62M |
8.31% |
2023-06-29 |
Vanguard Strategic Equity Fund |
1.32M |
14.60M |
3.16% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
1.12M |
12.43M |
2.69% |
2023-07-30 |
Vanguard Explorer Fund, Inc. |
873.65K |
9.44M |
2.09% |
2023-08-30 |
iShares Russell 2000 ETF |
563.33K |
6.10M |
1.35% |
2023-06-29 |
Vanguard Extended Market Index Fund |
504.10K |
5.58M |
1.21% |